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Abstract 
Background: There is often a finite progression-free interval of time between one systemic 
therapy and the next when treating patients with advanced cancer. While it appears that 
progression-free survival (PFS) between systemic therapies tends to get shorter for a number 
of factors, there has not been a formal evaluation of diverse tumor types in an advanced 
cancer population treated with commercially-available systemic therapies.  
Methods: In an attempt to clarify the relationship between PFS between subsequent systemic 
therapies, we analyzed the records of 165 advanced cancer patients coming to our clinic for 
consideration for participation in six different phase I clinical trials requiring detailed and 
extensive past medical treatment history documentation. 
Results: There were 77 men and 65 women meeting inclusion criteria with a median age at 
diagnosis of 55.3 years (range 9.4-81.6). The most common cancer types were colorectal 
(13.9%), other gastrointestinal (11.8%), prostate (11.8%). A median of 3 (range 1-11) systemic 
therapies were received prior to phase I evaluation. There was a significant decrease in PFS in 
systemic therapy for advanced disease from treatment 1 to treatment 2 to treatment 3 (p = 
0.002), as well as, from treatment 1 through treatment 5 (p < 0.001). 
Conclusions: In an advanced cancer population of diverse tumor types, we observe a statis-
tically significant decrease in PFS with each successive standard therapy. Identification of new 
therapies that reverse this trend of decreasing PFS may lead to improved clinical outcomes. 
Key words: Progression-free survival, chemotherapy, advanced cancer, systemic therapy, phase I 
clinical trials 
Introduction 
The  treatment  of  advanced/metastatic  cancer 
often involves systemic chemotherapy. The most ro-
bust responses and lengthiest interval of time before 
disease progression is usually observed with first-line 
therapy1,2,3.  Often,  when  progression  occurs  on 
first-line therapy, subsequent systemic therapies are 
offered  in  patients  who  are  eligible  for  additional 
therapy  based  on  clinical  attributes  such  as  perfor-
mance  status  and  acceptable  laboratory  parameters. 
Subsequent  therapies  are  selected  based  on  tumor 
type  and  treatment  guidelines,  availability  of  ap-
proved agents or off-label use of approved agents, or 
when  feasible,  eligibility  to  participate  in  a  clinical 
trial involving systemic therapy of an investigational 
Ivyspring  
International Publisher    Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
8 
agent. It has been noted that the interval of time be-
tween  subsequent  therapies  in  advanced/metastatic 
cancer is reduced after each treatment. For example, 
progression-free  survival  (PFS)  shortens  such  that 
Treatment A > Treatment B > Treatment C > Treat-
ment D, and so on1,2,3. Examination of the relationship 
between PFS and its impact on disease progression in 
advanced/metastatic  cancer  patients  leading  up  to 
evaluation for participation in a phase I clinical trial 
has been limited.  
Clinical factors that may affect the length of sur-
vival during phase I clinical trials for patients with 
advanced  cancers  have  been  identified.  Patients  re-
ceiving more than five prior treatments had a trend 
toward  shorter  survival4.  A  longer  median  PFS  has 
been  observed  in  lung  cancer  patients  treated  on 
phase  I  studies  that  had  received  two  or  less  prior 
therapies  compared  to  lung  cancer  patients  treated 
with more than two prior therapies5. While it appears 
that PFS tends to get shorter for a number of factors 
(e.g. tumor progression, toxicity, or patient wishes), 
there has not been a formal evaluation in an advanced 
cancer population of diverse tumor types treated with 
commercially-available  systemic  therapies.  We  ex-
amined PFS between systemic therapies of commer-
cially available agents prior to presenting for a phase I 
clinical trial evaluation at our institution.  
Materials and Methods 
Participants were all adults with a diagnosis of 
advanced/metastatic cancer at the time of signed in-
formed consent for screening for a Phase I clinical trial 
at our center. All patients were selected for inclusion 
in this analysis because they consented for at least one 
of six of our phase I trials which require detailed past 
medical treatment histories, including prior treatment 
start and stop dates, past surgeries and radiotherapy 
treatment dates, as part of screening. Clinical charac-
teristics collected include: subject diagnosis, histology, 
age, gender, stage at diagnosis, prior chemotherapy, 
prior surgery and radiation therapy, and PFS on sys-
temic  therapy  for  advanced/metastatic  cancer  was 
calculated  from  start  of  the  first  systemic  therapy 
regimen for advanced/metastatic cancer (txn) to the 
start of the next subsequent systemic therapy (txn+1), 
then txn+1 and txn+2, and so on. PFS between consecu-
tive  systemic  therapies  were  calculated  using  the 
Jonckheere-Terpstra test. NOTE: if there was a pallia-
tive  surgical  or  radiation  intervention  between  one 
type of systemic therapy (e.g. txn+2 and txn+3 ), then 
additional  PFS  calculations  were  resumed  from  the 
starting point txn+3 to the start of txn+4, such that PFS 
was not calculated between start of txn+2 and txn+3.  
 
Each  patient’s  medical  history  was  reviewed 
from the time of cancer diagnosis to presentation at 
our  institution  for  clinical  trial  evaluation  to  deter-
mine the PFS for each line of therapy. Surgery, radi-
otherapy,  herbal  supplements,  and  investigational 
therapies were censored. Standard therapies given to 
patients subsequent to investigational therapies were 
censored  from  the  data  set.  Progression  dates  were 
defined by the start date  of the  next chemotherapy 
agent given. When the exact day of the month for start 
or stop of a therapy was not provided, the 15th of the 
month  was  assigned.  When  start  and  progression 
dates lacked information about the specific month or 
year, the treatment information was censored.  
Results 
Patient Characteristics 
We reviewed the patient records of 165 unique 
patients that were evaluated for participation in six 
phase  I  trials.  Due  to  a  lack  of  specific  start/stop 
dates, 25 patients had at least one treatment censored 
for analysis; with one of these patients not having PFS 
that could be calculated for this study. Seventeen of 
these twenty-five patients were diagnosed as having 
less than stage IV disease, with the majority of cen-
sored treatments (radiation, surgery, or neoadjuvant 
or  adjuvant  chemotherapy)  occurring  in  the 
non-advanced/metastatic  setting.  One  hundred  for-
ty-four patients met criteria for receiving at least one 
prior  non-investigational  systemic  therapy  for  ad-
vanced/metastatic cancer prior to coming for a phase 
I  treatment  evaluation.  There  were  77  men  and  65 
women;  median  age  at  cancer  diagnosis  was  55.3 
years  (range,  9.4  –  81.6  years).  The  most  common 
types  were:  colorectal  cancer  (n=20  (13.9%)),  other 
gastrointestinal  cancer  (n=17  (11.8%)),  adenocarci-
noma  of  the  prostate  (n=17  (11.8%)),  non-small  cell 
lung  cancer  (NSCLC)  (n=13  (9.0%)),  breast  cancer 
(n=12 (8.3%)), ovarian cancer (n=11 (7.6%)), and ade-
nocarcinoma  of  the  pancreas  (n=9  (6.3%))  (Table  I). 
Patients  had  a  median  of  three  chemotherapy  or 
hormonal treatments (mean, 3.32 treatments; range, 1 
– 11 treatments).  
Two of the 144 patients did not receive a second 
systemic therapy prior to evaluation at our center, so 
PFS  could  be  calculated  for  the  remaining  142  pa-
tients. The PFS from txn to txn+3 was significantly de-
creased (p = 0.001850) (Figure 1). Few advanced can-
cers have more than four lines of FDA-approved or 
consensus guidelines recommendations for systemic 
therapy, thus we examined the time to progression of 
the first five treatments (p = 2.938e-07) (Figure 2).  Journal of Cancer 2012, 3 
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Table I. Patient Diagnoses, Gender, Median Age at Diagnosis and Median Number of Therapies  
  Number of Patients*  Male  Female  Median Age at Diagnosis 
(range) (in years) 
Median Therapies 
(range) (in years)  
Total  142  77  65  55.7 (9.4-81.6)  3 (1-11) 
Colorectal  20  11  9  55.3 (33.1-79.9)  4 (2-9) 
Other Gastrointestinal  17  12  5  54.0 (9.4-72.9)  2 (1-10) 
Prostate  17  17  0  60.3 (52.0-75.2)  3 (2-8) 
Breast  12  1  11  44.9 (28.0-57.3)  7 (3-11) 
Non-small-cell Lung  13  9  4  63.9 (41.6-81.6)  3 (1-4) 
Ovarian  11  0  11  59.8 (44.2-75.3)  4 (2-9) 
Pancreatic  9  6  3  61.0 (31.7-79.6)  1 (1-4) 
Gynecological  8  0  8  39.6 (24.4-69.7)  1.5 (1-3) 
Head and Neck  8  6  2  51.9 (45.3-72.3)  2 (1-8) 
Skin  7  6  1  48.2 (32.0-73.3)  2 (1-3) 
Other  6  1  5  52.4 (39.5-62.7)  2 (1-5) 
Small-cell Lung  4  0  4  55.9 (50.0-66.2)  2.5 (2-3) 
Genitourinary  3  3  0  53.2 (19.5-66.6)  3 (2-4) 
Sarcoma  3  2  1  66.7 (29.9-78.0)  2 (1-3) 
Thoracic  3  2  1  37.9 (19.6-60.1)  1 (1-4) 
Adrenal  1  1  0  54.0 (54.0-54.0)  1 (1-1) 
"Other" include: unknown primary (n=2), carcinoma (n=1), eccrine sweat gland (n=1), leiomyosarcoma (n=1), occular melanoma (n=1). 
*Does not include patients that were censored from analysis. 
 
 
 
 
 
Figure 1. PFS in days from first systemic therapy to third systemic therapy. Boxplot detail showing significant 
decrease in PFS calculated for first systemic therapy (TX1), second systemic therapy (TX2), and third systemic therapy 
(TX3) in days.   Journal of Cancer 2012, 3 
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Figure 2. PFS in days from first systemic therapy to fifth systemic therapy. Boxplot detail showing significant 
decrease in PFS calculated for first systemic therapy (TX1), second systemic therapy (TX2), third systemic therapy (TX3), 
fourth systemic therapy (TX4), and fifth systemic therapy (TX5) in days. 
 
Discussion 
Statistical  analyses  revealed  that  there  was  a 
significant  downward  trend  in  PFS  for  patients  on 
three  standard  therapies  (p  =  0.001850)  (Figure  1). 
Most patients with advanced cancers have no more 
than four lines of approved treatment, we also exam-
ined the PFS of the first five treatments, again finding 
a significant downward trend (p = 2.938e-07) (Figure 
2). 
Other  reports  support  these  findings  of  de-
creased PFS with subsequent therapies. In colorectal 
cancer,  the  median  PFS  is  6-10.6  months6-15,  2.3-7.3 
months16-20, and 5.3-5.4 months21,22 for first-, second-, 
and  third-line  systemic  therapies;  respectively.  In 
NSCLC,  the  median  PFS  is  4.2-13.1  months23-33  and 
1.7-4.6 months34-43 for first- and second line-treatment; 
respectively. In gastro-esophageal cancer, the median 
PFS  is  3.9-7.0  months44-49 and  1.8-4.1  months50-52  for 
first- and second-line therapy; respectively. The least 
favorable results are in patients with advanced pan-
creatic  cancer,  where  the  median  PFS  is  3.3-6.4 
months53,54 and  1.4-4.1  months55-59  for  first-  and  se-
cond-line treatment; respectively (Table II).  
A reversal of decreasing PFS with therapy may 
suggest a change in the expected course of the disease. 
Recent examples of new therapies that have dramati-
cally  changed  the  disease  course  for  patients  with 
advanced  cancer  include  targeted  cancer  therapies 
such as imatinib for chronic myelogenous leukemia 
and gastrointestinal stromal tumors (GIST) and erlo-
tinib  for  NSCLC.  In  GIST  patients  treated  with 
imatinib, a specific exon mutation in the tumor corre-
lates  with  a  higher  response  rate,  PFS,  and  overall 
survival (OS)60-62. In NSCLC, it is the activating tyro-
sine kinase mutation in the tumor’s EGFR gene that 
dramatically  sensitizes  this  cancer  to  erlotinib  and 
gefitinib63-67. These mutations had first been observed 
in clinical  subgroups of NSCLC patients, primarily, 
Asian  never-smoker  women  with  adenocarcino-
ma60,68-71.  Potential  “therapeutic  efficacy”  subgroups 
may be recognized when a reversal in the expected 
decreasing PFS during therapy is observed. 
 
Table II. Progression-free Survival for Successive Treat-
ments in Supporting Articles. KEY: TX 1 – PFS for first-line 
systemic therapy, TX 2- PFS for second-line systemic 
therapy, TX 3- PFS for third-line systemic therapy. 
Cancer Type  TX 1 
(months) 
TX 2 
(months) 
TX 3 
(months) 
Colorectal  6–10.7  2.3–7.3  5.3-5.4 
Non-small cell Lung  4.2–13.1  1.7-4.6  - 
Gastro-esophageal  3.9-7.0  1.8-4.1  - 
Pancreatic  3.3-6.4  1.4-4.1  - 
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